Wound Management News

Implementing a rapid molecular diagnostic test for MRSA among patients with purulent skin infections did not reduce the empiric use of MRSA-active antibiotics for patients with non-MRSA infections, according to researchers from the University of California, Los Angeles.

XBiotech has begun a phase 2 study based on anti-interleukin-1 alpha therapeutic antibody for treating patients with pyoderma gangrenosum.

Organogenesis announced that it has acquired Dermagraft assets from Shire.

Medical technology company BD Diagnostics has received FDA clearance to market a molecular assay capable of detecting newly emerging strains of MRSA, according to a company news release.

Since the implementation of the Veterans Affairs MRSA Prevention Initiative in long-term care facilities in January 2009, the overall rate of health care-associated MRSA infections decreased by 36%, according to study findings in the American Journal of Infection Control.

Scioderm announced a phase 2b study on the efficacy and safety of its novel topical therapy for treating nonhealing wounds in patients with epidermolysis bullosa has begun.

Mortality from non-neoplastic skin disease was uncommon but occurred primarily in elderly patients, with chronic ulcers and cellulitis constituting common underlying causes, according to recent study results.

Oculus Innovative Sciences announced it has received regulatory approval in Mexico for its hydrogel treatment for hypertrophic and keloid scars.

Laser treatment, particularly ablative fractional laser resurfacing, is safe and effective for burn and traumatic scars and should be utilized in combination therapies, according to a consensus of laser therapy physicians.

The FDA has given 510(k) clearance for a hydrogel treatment of hypertrophic and keloid scars resulting from burns, general surgical procedures and trauma wounds, Oculus Innovative Sciences announced.